ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD)

NCT05889273 · clinicaltrials.gov ↗

PHASE2

Phase

ENROLLING_BY_INVITATION

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Autism Spectrum Disorder

Interventions

DRUG: ML-004 (IR)/(ER) tablet

Sponsor

MapLight Therapeutics